ARTICLE | Finance
Lyfe lessons: Bay Area VC growing global footprint with $935M new fund
With its roots in China, Lyfe Capital will continue to build bridges between its Western and Asian therapeutics, diagnostics and medtech plays
May 7, 2022 2:13 AM UTC
Having raised its largest fund to date, Lyfe Capital plans to deepen its U.S. base while continuing to help its portfolio of U.S. and Asian biotech, device and diagnostics companies find partners and run trials around the globe.
The firm’s $935 million fourth fund brings the assets under management for the Menlo Park, Calif.-based venture firm to $2 billion. For portfolio companies, founder and Managing Partner James Zhao said Lyfe gives biotechs expertise in running trials in the U.S. and Asia and access to relationships with global biopharmas. For LPs, the firm offers its mostly Western LPs exposure to deal flow in Asia, via a U.S. fund whose teams’ roots are in China...